Loading…
Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study
Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72...
Saved in:
Published in: | The European journal of contraception & reproductive health care 2014-02, Vol.19 (1), p.29-38 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3 |
---|---|
cites | cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3 |
container_end_page | 38 |
container_issue | 1 |
container_start_page | 29 |
container_title | The European journal of contraception & reproductive health care |
container_volume | 19 |
creator | Short, Mary Dallay, Dominique Omokanye, Salmon Stauch, Kathrin Inki, Pirjo |
description | Abstract
Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe.
Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented.
Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively.
Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use. |
doi_str_mv | 10.3109/13625187.2013.862230 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_13625187_2013_862230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3216695491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwDxCyxIVDvdhj54tD0aoqH1IlLnCOHGeydeW1g-1slX-Pw7YIOPTkOTzP6xm9RfGas43grH3PRQUlb-oNMC42TQUg2JPilMtaUFY38DTPGaErc1K8iPGWZVCK6nlxAhKatoTmtDhstcYpqd5YkxbiR2K921Glk3G7czIFv8OYZ-qdXYj2LgW1CsY7Yhy5moOf8APZknTn6YIqrEqcMPsHPCfOO2pcwnBAtzrKkpjmYXlZPBuVjfjq_j0rfny6-n75hV5_-_z1cntNtZRVon0plO7rSusK2hI5DGwQrZa1Ag3QK6YVYMvbQTGQyHAUQpYthx40l-OgxFnx7pibt_o550u6vYkarVUO_Rw7LlspmKhZndG3_6G3fg55499UDQ0AbzIlj5TOZ8aAYzcFs1dh6Tjr1l66h166tZfu2EvW3tyHz_0ehz_SQxEZ-HgEjBt92Ks7H-zQJbVYH8agnDZxjX_0i4t_Em5Q2XSjVcC_Dnks4Bez8rE1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497282218</pqid></control><display><type>article</type><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</creator><creatorcontrib>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</creatorcontrib><description>Abstract
Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe.
Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented.
Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively.
Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</description><identifier>ISSN: 1362-5187</identifier><identifier>EISSN: 1473-0782</identifier><identifier>DOI: 10.3109/13625187.2013.862230</identifier><identifier>PMID: 24289528</identifier><identifier>CODEN: ECRCFK</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Adult ; Birth control ; Continuation ; Contraception - methods ; Contraceptive Agents, Female - therapeutic use ; Desogestrel - therapeutic use ; Device Removal - statistics & numerical data ; Drug Implants - therapeutic use ; Etonogestrel releasing-subdermal implant ; Female ; France ; Humans ; Intrauterine devices ; Intrauterine Devices, Medicated - utilization ; Ireland ; IUD ; Levonorgestrel - therapeutic use ; Levonorgestrel releasing-intrauterine system ; Long-acting reversible contraceptives ; Longitudinal Studies ; Menstruation ; Middle Aged ; Patient Acceptance of Health Care ; Prospective Studies ; Satisfaction ; Slovakia ; Transplants & implants ; United Kingdom ; Womens health ; Young Adult</subject><ispartof>The European journal of contraception & reproductive health care, 2014-02, Vol.19 (1), p.29-38</ispartof><rights>2014 The European Society of Contraception and Reproductive Health 2014</rights><rights>Copyright Taylor & Francis Ltd. Feb 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</citedby><cites>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24289528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Short, Mary</creatorcontrib><creatorcontrib>Dallay, Dominique</creatorcontrib><creatorcontrib>Omokanye, Salmon</creatorcontrib><creatorcontrib>Stauch, Kathrin</creatorcontrib><creatorcontrib>Inki, Pirjo</creatorcontrib><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><title>The European journal of contraception & reproductive health care</title><addtitle>Eur J Contracept Reprod Health Care</addtitle><description>Abstract
Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe.
Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented.
Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively.
Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</description><subject>Adult</subject><subject>Birth control</subject><subject>Continuation</subject><subject>Contraception - methods</subject><subject>Contraceptive Agents, Female - therapeutic use</subject><subject>Desogestrel - therapeutic use</subject><subject>Device Removal - statistics & numerical data</subject><subject>Drug Implants - therapeutic use</subject><subject>Etonogestrel releasing-subdermal implant</subject><subject>Female</subject><subject>France</subject><subject>Humans</subject><subject>Intrauterine devices</subject><subject>Intrauterine Devices, Medicated - utilization</subject><subject>Ireland</subject><subject>IUD</subject><subject>Levonorgestrel - therapeutic use</subject><subject>Levonorgestrel releasing-intrauterine system</subject><subject>Long-acting reversible contraceptives</subject><subject>Longitudinal Studies</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>Patient Acceptance of Health Care</subject><subject>Prospective Studies</subject><subject>Satisfaction</subject><subject>Slovakia</subject><subject>Transplants & implants</subject><subject>United Kingdom</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>1362-5187</issn><issn>1473-0782</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoqXwDxCyxIVDvdhj54tD0aoqH1IlLnCOHGeydeW1g-1slX-Pw7YIOPTkOTzP6xm9RfGas43grH3PRQUlb-oNMC42TQUg2JPilMtaUFY38DTPGaErc1K8iPGWZVCK6nlxAhKatoTmtDhstcYpqd5YkxbiR2K921Glk3G7czIFv8OYZ-qdXYj2LgW1CsY7Yhy5moOf8APZknTn6YIqrEqcMPsHPCfOO2pcwnBAtzrKkpjmYXlZPBuVjfjq_j0rfny6-n75hV5_-_z1cntNtZRVon0plO7rSusK2hI5DGwQrZa1Ag3QK6YVYMvbQTGQyHAUQpYthx40l-OgxFnx7pibt_o550u6vYkarVUO_Rw7LlspmKhZndG3_6G3fg55499UDQ0AbzIlj5TOZ8aAYzcFs1dh6Tjr1l66h166tZfu2EvW3tyHz_0ehz_SQxEZ-HgEjBt92Ks7H-zQJbVYH8agnDZxjX_0i4t_Em5Q2XSjVcC_Dnks4Bez8rE1</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Short, Mary</creator><creator>Dallay, Dominique</creator><creator>Omokanye, Salmon</creator><creator>Stauch, Kathrin</creator><creator>Inki, Pirjo</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201402</creationdate><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><author>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Birth control</topic><topic>Continuation</topic><topic>Contraception - methods</topic><topic>Contraceptive Agents, Female - therapeutic use</topic><topic>Desogestrel - therapeutic use</topic><topic>Device Removal - statistics & numerical data</topic><topic>Drug Implants - therapeutic use</topic><topic>Etonogestrel releasing-subdermal implant</topic><topic>Female</topic><topic>France</topic><topic>Humans</topic><topic>Intrauterine devices</topic><topic>Intrauterine Devices, Medicated - utilization</topic><topic>Ireland</topic><topic>IUD</topic><topic>Levonorgestrel - therapeutic use</topic><topic>Levonorgestrel releasing-intrauterine system</topic><topic>Long-acting reversible contraceptives</topic><topic>Longitudinal Studies</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>Patient Acceptance of Health Care</topic><topic>Prospective Studies</topic><topic>Satisfaction</topic><topic>Slovakia</topic><topic>Transplants & implants</topic><topic>United Kingdom</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Short, Mary</creatorcontrib><creatorcontrib>Dallay, Dominique</creatorcontrib><creatorcontrib>Omokanye, Salmon</creatorcontrib><creatorcontrib>Stauch, Kathrin</creatorcontrib><creatorcontrib>Inki, Pirjo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of contraception & reproductive health care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Short, Mary</au><au>Dallay, Dominique</au><au>Omokanye, Salmon</au><au>Stauch, Kathrin</au><au>Inki, Pirjo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</atitle><jtitle>The European journal of contraception & reproductive health care</jtitle><addtitle>Eur J Contracept Reprod Health Care</addtitle><date>2014-02</date><risdate>2014</risdate><volume>19</volume><issue>1</issue><spage>29</spage><epage>38</epage><pages>29-38</pages><issn>1362-5187</issn><eissn>1473-0782</eissn><coden>ECRCFK</coden><abstract>Abstract
Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe.
Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented.
Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively.
Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>24289528</pmid><doi>10.3109/13625187.2013.862230</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1362-5187 |
ispartof | The European journal of contraception & reproductive health care, 2014-02, Vol.19 (1), p.29-38 |
issn | 1362-5187 1473-0782 |
language | eng |
recordid | cdi_crossref_primary_10_3109_13625187_2013_862230 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Adult Birth control Continuation Contraception - methods Contraceptive Agents, Female - therapeutic use Desogestrel - therapeutic use Device Removal - statistics & numerical data Drug Implants - therapeutic use Etonogestrel releasing-subdermal implant Female France Humans Intrauterine devices Intrauterine Devices, Medicated - utilization Ireland IUD Levonorgestrel - therapeutic use Levonorgestrel releasing-intrauterine system Long-acting reversible contraceptives Longitudinal Studies Menstruation Middle Aged Patient Acceptance of Health Care Prospective Studies Satisfaction Slovakia Transplants & implants United Kingdom Womens health Young Adult |
title | Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A11%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acceptability%20of%20long-acting,%20progestin-only%20contraception%20in%20Europe:%20A%20two-year%20prospective,%20non-interventional%20study&rft.jtitle=The%20European%20journal%20of%20contraception%20&%20reproductive%20health%20care&rft.au=Short,%20Mary&rft.date=2014-02&rft.volume=19&rft.issue=1&rft.spage=29&rft.epage=38&rft.pages=29-38&rft.issn=1362-5187&rft.eissn=1473-0782&rft.coden=ECRCFK&rft_id=info:doi/10.3109/13625187.2013.862230&rft_dat=%3Cproquest_cross%3E3216695491%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1497282218&rft_id=info:pmid/24289528&rfr_iscdi=true |